TAXOTERE

국가: 이스라엘

언어: 영어

출처: Ministry of Health

유효 성분:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

제공처:

SANOFI - AVENTIS ISRAEL LTD

ATC 코드:

L01CD02

약제 형태:

CONCENTRATE FOR SOLUTION FOR INFUSION

관리 경로:

I.V

Manufactured by:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

치료 그룹:

DOCETAXEL

치료 징후:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

승인 날짜:

2012-11-01